Johns Hopkins Technology Transfer has licensed a new nanotechnology to a Gaithersburg startup for the development of cancer therapies.
The license for Artificial Immune nanotechnology was granted to NexImmune, formed in part by Johns Hopkins University School of Medicine faculty members. The staff members are involved in the development of the Artificial Immune technology.